1. Poston JN (1999) Positive Leu-MI immuno-histochemistry and diagnosis of the lymphoma cases described by Hodgkin in 1832. Appl Immunohistochem Mol Morphol 7:6–8
2. Horner MJ, Ries LA, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) (2009) SEER Cancer Statistics Review, 1975-2006. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2006/ based on November 2008 SEER data submission, posted to the SEER web site
3. Hutchings M, Loft A, Hansen M et al (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24(3):146–150
4. Döbert N, Menzel C, Hamscho N et al (2004) Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Q J Nucl Med Mol Imaging 48(1):33–38
5. Hoffmann M, Kletter K, Diemling M et al (1999) Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10:1185–1189